clinical trial for retatrutide peptide trials Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped Lilly Prepares for Retatrutide FDA

How GLP1s dont improve fertility: GLP1s do not directly boost egg quality, embryo quality, or ovarian reserve

We propose a redox-guided, phenotype-aware framework for future trials, emphasizing biomarker-anchored outcomes and systems-level integration

Applying them at different times of day (for example, minoxidil in the morning and GHK-Cu at night) prevents interference and maximizes absorption

November 14th, 2025: Three New Jersey Cases Added to Expanding GLP-1 Drug MDL A federal judicial panel has transferred three additional lawsuits from New Jersey into the growing multidistrict litigation involving claims that Eli Lilly and Novo Nordisk minimized the safety risks associated with GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Trulicity